Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs
Copyright ©ERS 2021..
Conventional molecular tests for detecting Mycobacterium tuberculosis complex (MTBC) drug resistance on clinical samples cover a limited set of mutations. Whole-genome sequencing (WGS) typically requires culture.Here, we evaluated the Deeplex Myc-TB targeted deep-sequencing assay for prediction of resistance to 13 anti-tuberculous drugs/drug classes, directly applicable on sputum.With MTBC DNA tests, the limit of detection was 100-1000 genome copies for fixed resistance mutations. Deeplex Myc-TB captured in silico 97.1-99.3% of resistance phenotypes correctly predicted by WGS from 3651 MTBC genomes. On 429 isolates, the assay predicted 92.2% of 2369 first- and second-line phenotypes, with a sensitivity of 95.3% and a specificity of 97.4%. 56 out of 69 (81.2%) residual discrepancies with phenotypic results involved pyrazinamide, ethambutol and ethionamide, and low-level rifampicin or isoniazid resistance mutations, all notoriously prone to phenotypic testing variability. Only two out of 91 (2.2%) resistance phenotypes undetected by Deeplex Myc-TB had known resistance-associated mutations by WGS analysis outside Deeplex Myc-TB targets. Phenotype predictions from Deeplex Myc-TB analysis directly on 109 sputa from a Djibouti survey matched those of MTBSeq/PhyResSE/Mykrobe, fed with WGS data from subsequent cultures, with a sensitivity of 93.5/98.5/93.1% and a specificity of 98.5/97.2/95.3%, respectively. Most residual discordances involved gene deletions/indels and 3-12% heteroresistant calls undetected by WGS analysis or natural pyrazinamide resistance of globally rare "Mycobacterium canettii" strains then unreported by Deeplex Myc-TB. On 1494 arduous sputa from a Democratic Republic of the Congo survey, 14 902 out of 19 422 (76.7%) possible susceptible or resistance phenotypes could be predicted culture-free.Deeplex Myc-TB may enable fast, tailored tuberculosis treatment.
| Errataetall: |
CommentIn: Eur Respir J. 2021 Mar 18;57(3):. - PMID 33737379 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
The European respiratory journal - 57(2021), 3 vom: 31. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jouet, Agathe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antitubercular Agents |
|---|
| Anmerkungen: |
Date Completed 02.07.2021 Date Revised 10.11.2022 published: Electronic-Print CommentIn: Eur Respir J. 2021 Mar 18;57(3):. - PMID 33737379 Citation Status MEDLINE |
|---|
| doi: |
10.1183/13993003.02338-2020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315148888 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315148888 | ||
| 003 | DE-627 | ||
| 005 | 20231225154302.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1183/13993003.02338-2020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1050.xml |
| 035 | |a (DE-627)NLM315148888 | ||
| 035 | |a (NLM)32943401 | ||
| 035 | |a (PII)2002338 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jouet, Agathe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.07.2021 | ||
| 500 | |a Date Revised 10.11.2022 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a CommentIn: Eur Respir J. 2021 Mar 18;57(3):. - PMID 33737379 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright ©ERS 2021. | ||
| 520 | |a Conventional molecular tests for detecting Mycobacterium tuberculosis complex (MTBC) drug resistance on clinical samples cover a limited set of mutations. Whole-genome sequencing (WGS) typically requires culture.Here, we evaluated the Deeplex Myc-TB targeted deep-sequencing assay for prediction of resistance to 13 anti-tuberculous drugs/drug classes, directly applicable on sputum.With MTBC DNA tests, the limit of detection was 100-1000 genome copies for fixed resistance mutations. Deeplex Myc-TB captured in silico 97.1-99.3% of resistance phenotypes correctly predicted by WGS from 3651 MTBC genomes. On 429 isolates, the assay predicted 92.2% of 2369 first- and second-line phenotypes, with a sensitivity of 95.3% and a specificity of 97.4%. 56 out of 69 (81.2%) residual discrepancies with phenotypic results involved pyrazinamide, ethambutol and ethionamide, and low-level rifampicin or isoniazid resistance mutations, all notoriously prone to phenotypic testing variability. Only two out of 91 (2.2%) resistance phenotypes undetected by Deeplex Myc-TB had known resistance-associated mutations by WGS analysis outside Deeplex Myc-TB targets. Phenotype predictions from Deeplex Myc-TB analysis directly on 109 sputa from a Djibouti survey matched those of MTBSeq/PhyResSE/Mykrobe, fed with WGS data from subsequent cultures, with a sensitivity of 93.5/98.5/93.1% and a specificity of 98.5/97.2/95.3%, respectively. Most residual discordances involved gene deletions/indels and 3-12% heteroresistant calls undetected by WGS analysis or natural pyrazinamide resistance of globally rare "Mycobacterium canettii" strains then unreported by Deeplex Myc-TB. On 1494 arduous sputa from a Democratic Republic of the Congo survey, 14 902 out of 19 422 (76.7%) possible susceptible or resistance phenotypes could be predicted culture-free.Deeplex Myc-TB may enable fast, tailored tuberculosis treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Gaudin, Cyril |e verfasserin |4 aut | |
| 700 | 1 | |a Badalato, Nelly |e verfasserin |4 aut | |
| 700 | 1 | |a Allix-Béguec, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Duthoy, Stéphanie |e verfasserin |4 aut | |
| 700 | 1 | |a Ferré, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Diels, Maren |e verfasserin |4 aut | |
| 700 | 1 | |a Laurent, Yannick |e verfasserin |4 aut | |
| 700 | 1 | |a Contreras, Sandy |e verfasserin |4 aut | |
| 700 | 1 | |a Feuerriegel, Silke |e verfasserin |4 aut | |
| 700 | 1 | |a Niemann, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a André, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Kaswa, Michel K |e verfasserin |4 aut | |
| 700 | 1 | |a Tagliani, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Cabibbe, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Mathys, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Cirillo, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a de Jong, Bouke C |e verfasserin |4 aut | |
| 700 | 1 | |a Rigouts, Leen |e verfasserin |4 aut | |
| 700 | 1 | |a Supply, Philip |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The European respiratory journal |d 1989 |g 57(2021), 3 vom: 31. März |w (DE-627)NLM012664782 |x 0903-1936 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2021 |g number:3 |g day:31 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1183/13993003.02338-2020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2021 |e 3 |b 31 |c 03 | ||